Cristina Gasparetto | Scholars@Duke

Cristina Gasparetto
Professor of Medicine

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1993

Contact Information

2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
DUMC Box 3961, Durham, NC 27710
gaspa001@mc.duke.edu (919) 668-1000

Background
Education, Training, & Certifications
- Fellow in Hematology/Oncology, Medicine, Duke University 1996 - 1999
- Medical Resident, Medicine, Duke University 1993 - 1996
- M.D., Sapienza University of Rome (Italy) 1986
Duke Appointment History
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2012 - 2018
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2008 - 2012
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2002 - 2008
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2002
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999
Research
Selected Grants
- BB2121 MM 003 2019 - 2024
- Venetoclax ABT-199 2018 - 2023
- M15 654 2018 - 2023
- NP39403 2018 - 2023
- A Phase 1, Open Label Study to evaluate the safety Pharmacokinetic, Pharmacodynamic and clinical activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecifi Antibody In Patient 2018 - 2023
- AbbVie M15 538 2018 - 2023
- Protocol 54767414MMY2004 Phase 2 2017 - 2022
- Phase III double blind study of Bortezomib and Dex in combination with Venetoclax or Placebo in R/R MM 2016 - 2021
- A Feasibility Phase II study of BEAM followed by MLN 9708 Maintenance therapy in high risk MM patients 2016 - 2021
- Ph 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone 2016 - 2021
- Phase Ib/2 Study of Selinexor (KPT330) for R/R MM 2016 - 2021
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- Phase 1/2 Open label study of SL-401 with Pom/Dex in R/R MM 2016 - 2021
- Phase III study of Pomalidomide and low dose Dex with or without Pembrolizumab (MK3475) in MM 2016 - 2021
- An Observational Study on Newly Diagnosed MM to assess the realtionship between patient outcomes, treatment regimens 2013 - 2020
- A Phase I Study of ABT-199 Monotherapy in R/R Multiple Myeloma 2015 - 2020
- Phase 1/2b study of Ibrutinib with Carlfizomib with R/R Myeloma 2013 - 2019
- Study to evaluate the safety of SAR650984 (isatuximab) in R/R MM pts 2017 - 2019
- NEOD001 2017 - 2018
- A Phase II study of Filanesib (ARRY-520) with patients with Advanced Multiple Myeloma 2014 - 2018
- CELGENE MULTIPLE MYELOMA TUMOR PRACTICUM 2017
- Randomized Phase II trial study of lenalidomide, bortezomib and dexamethsone (RVD) in new MM pts 2016 - 2017
- Phase II, study of Selinexor KPT-330 Carlf, and Dexa, in R/R MM pts 2016 - 2017
- KPT-330 (KCP-330-011) SLAM in R/R MM 2015 - 2017
- Dendritic Cell Based Vaccination for Multiple Myeloma awarded by National Institutes of Health 2002 - 2007
Industry Relationships
- Amgen, Inc.
- Bristol-Myers Squibb
- Caelum
- Celgene Corporation
- Janssen AI (Johnson & Johnson)
- Karyopharm Therapeutics Inc
- Millennium Pharmaceuticals, Inc. (Takeda)
- PPD
- adaptive biotechnology corporation
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Ailawadhi, Sikander, Sundar Jagannath, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Brian G. M. Durie, et al. “Connect MM Registry as a national reference for United States multiple myeloma patients..” Cancer Med 9, no. 1 (January 2020): 35–42. https://doi.org/10.1002/cam4.2656.
    Full Text Link to Item
  - Terebelo, Howard R., Rafat Abonour, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Sundar Jagannath, et al. “Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry..” Br J Haematol 187, no. 5 (December 2019): 602–14. https://doi.org/10.1111/bjh.16139.
    Full Text Link to Item
  - Gopalakrishnan, Sathish, Anita D’Souza, Emma Scott, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, et al. “Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma..” Biol Blood Marrow Transplant 25, no. 4 (April 2019): 683–88. https://doi.org/10.1016/j.bbmt.2018.12.141.
    Full Text Link to Item
  - Stadtmauer, Edward A., Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial..” J Clin Oncol 37, no. 7 (March 1, 2019): 589–97. https://doi.org/10.1200/JCO.18.00685.
    Full Text Link to Item
  - Zheng, Jing, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Jagadish Kummetha Venkta, Cleopatra Kozlowski, et al. “Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade..” Cancer Lett 440–441 (January 2019): 1–10. https://doi.org/10.1016/j.canlet.2018.10.003.
    Full Text Link to Item
  - Bahlis, Nizar J., Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, et al. “Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma..” Blood 132, no. 24 (December 13, 2018): 2546–54. https://doi.org/10.1182/blood-2018-06-858852.
    Full Text Link to Item
  - Abonour, Rafat, Lynne Wagner, Brian G. M. Durie, Sundar Jagannath, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry..” Ann Hematol 97, no. 12 (December 2018): 2425–36. https://doi.org/10.1007/s00277-018-3446-y.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma..” Blood Cancer J 8, no. 8 (July 31, 2018). https://doi.org/10.1038/s41408-018-0104-5.
    Full Text Link to Item
  - Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM..” Blood Adv 2, no. 13 (July 10, 2018): 1608–15. https://doi.org/10.1182/bloodadvances.2018017186.
    Full Text Link to Item
  - Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, et al. “Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)..” Clin Lymphoma Myeloma Leuk 18, no. 7 (July 2018): 480-485.e3. https://doi.org/10.1016/j.clml.2018.04.007.
    Full Text Link to Item
  - Rifkin, Robert M., Sundar Jagannath, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry..” Clin Ther 40, no. 7 (July 2018): 1193-1202.e1. https://doi.org/10.1016/j.clinthera.2018.05.017.
    Full Text Link to Item
  - Sundaramoorthy, Pasupathi, Cristina Gasparetto, and Yubin Kang. “The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation..” Cancer Med, May 15, 2018. https://doi.org/10.1002/cam4.1543.
    Full Text Link to Item
  - Kumar, S. K., A. Dispenzieri, R. Fraser, F. Mingwei, G. Akpek, R. Cornell, M. Kharfan-Dabaja, et al. “Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time..” Leukemia 32, no. 4 (April 2018): 986–95. https://doi.org/10.1038/leu.2017.331.
    Full Text Link to Item
  - Htut, Myo, Anita D’Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, et al. “Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival..” Biol Blood Marrow Transplant 24, no. 3 (March 2018): 478–85. https://doi.org/10.1016/j.bbmt.2017.10.024.
    Full Text Link to Item
  - Zheng, Zhihong, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, and Yubin Kang. “Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma..” J Hematol Oncol 11, no. 1 (February 27, 2018). https://doi.org/10.1186/s13045-018-0575-7.
    Full Text Link to Item
  - Sivaraj, D., W. Bacon, G. D. Long, D. A. Rizzieri, M. E. Horwitz, K. M. Sullivan, Y. Kang, Z. Li, N. J. Chao, and C. Gasparetto. “High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma..” Bone Marrow Transplant 53, no. 1 (January 2018): 34–38. https://doi.org/10.1038/bmt.2017.208.
    Full Text Link to Item
  - Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M. Sullivan, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma..” Hematol Oncol 35, no. 4 (December 2017): 752–59. https://doi.org/10.1002/hon.2379.
    Full Text Link to Item
  - Shah, Jatin J., Rafat Abonour, Christina Gasparetto, James W. Hardin, Kathleen Toomey, Mohit Narang, Shankar Srinivasan, et al. “Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes..” Clin Lymphoma Myeloma Leuk 17, no. 9 (September 2017): 575-583.e2. https://doi.org/10.1016/j.clml.2017.06.013.
    Full Text Link to Item
  - Terebelo, Howard, Shankar Srinivasan, Mohit Narang, Rafat Abonour, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, et al. “Recognition of early mortality in multiple myeloma by a prediction matrix..” Am J Hematol 92, no. 9 (September 2017): 915–23. https://doi.org/10.1002/ajh.24796.
    Full Text Link to Item
  - Vogl, Dan T., Thomas G. Martin, Ravi Vij, Parameswaran Hari, Joseph R. Mikhael, David Siegel, Ka Lung Wu, Michel Delforge, and Cristina Gasparetto. “Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma..” Leuk Lymphoma 58, no. 8 (August 2017): 1872–79. https://doi.org/10.1080/10428194.2016.1263842.
    Full Text Link to Item
  - Anand, Sarah, Samantha Thomas, Terry Hyslop, Janet Adcock, Kelly Corbet, Cristina Gasparetto, Richard Lopez, et al. “Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization..” Biol Blood Marrow Transplant 23, no. 7 (July 2017): 1151–57. https://doi.org/10.1016/j.bbmt.2017.04.001.
    Full Text Link to Item
  - Voorhees, Peter M., Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, and David D. Hurd. “Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma..” Clin Lymphoma Myeloma Leuk 17, no. 7 (July 2017): 424–32. https://doi.org/10.1016/j.clml.2017.05.007.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, and Cristina Gasparetto. “Panobinostat for the management of multiple myeloma..” Future Oncol 13, no. 6 (March 2017): 477–88. https://doi.org/10.2217/fon-2016-0329.
    Full Text Link to Item
  - Kumar, S. K., N. S. Callander, M. Alsina, D. Atanackovic, J. S. Biermann, J. C. Chandler, C. Costello, et al. “Clinical practice guidelines in oncology.” Jnccn Journal of the National Comprehensive Cancer Network 15, no. 2 (February 1, 2017): 230–69.
  - Sivaraj, Dharshan, Michael M. Green, Zhiguo Li, Anthony D. Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D. Long, et al. “Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma..” Biol Blood Marrow Transplant 23, no. 2 (February 2017): 262–68. https://doi.org/10.1016/j.bbmt.2016.11.010.
    Full Text Link to Item
  - LeBlanc, T. W., A. Howson, W. Turell, P. Sheldon, S. C. Locke, S. A. Tuchman, C. Gasparetto, S. Kaura, Z. M. Khan, and A. P. Abernethy. “Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists..” Curr Oncol 23, no. 6 (December 2016): e598–604. https://doi.org/10.3747/co.23.3298.
    Full Text Link to Item
  - Sung, Anthony D., Julia A. M. Sung, Samantha Thomas, Terry Hyslop, Cristina Gasparetto, Gwynn Long, David Rizzieri, et al. “Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial..” Clin Infect Dis 63, no. 8 (October 15, 2016): 999–1006. https://doi.org/10.1093/cid/ciw451.
    Full Text Link to Item
  - Scott, Emma C., Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl, Muneer Abidi, et al. “Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis..” Biol Blood Marrow Transplant 22, no. 10 (October 2016): 1893–99. https://doi.org/10.1016/j.bbmt.2016.07.007.
    Full Text Link to Item
  - Rifkin, Robert M., Rafat Abonour, Jatin J. Shah, Jayesh Mehta, Mohit Narang, Howard Terebelo, Cristina Gasparetto, et al. “Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide..” Leuk Lymphoma 57, no. 9 (September 2016): 2228–31. https://doi.org/10.3109/10428194.2015.1132419.
    Full Text Link to Item
  - Green, Michael M. B., Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, et al. “Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery..” J Hematol Oncol 9, no. 1 (August 17, 2016). https://doi.org/10.1186/s13045-016-0301-2.
    Full Text Open Access Copy Link to Item
  - Sivaraj, Dharshan, Michael Martin Green, Abdullah Mucahit Ciftci, Mohammad Faizan Zahid, Angela Anne Johns, Maureen Ross, and Cristina Gasparetto. “Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach..” Clin Lymphoma Myeloma Leuk 16, no. 6 (June 2016): e95–100. https://doi.org/10.1016/j.clml.2016.03.002.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, et al. “NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016..” J Natl Compr Canc Netw 14, no. 4 (April 2016): 389–400. https://doi.org/10.6004/jnccn.2016.0046.
    Full Text Link to Item
  - Shah, Jatin J., Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William I. Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, et al. “Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma..” Blood 126, no. 20 (November 12, 2015): 2284–90. https://doi.org/10.1182/blood-2015-05-643320.
    Full Text Link to Item
  - Rifkin, Robert M., Rafat Abonour, Howard Terebelo, Jatin J. Shah, Cristina Gasparetto, James Hardin, Shankar Srinivasan, Rosanna Ricafort, Yasir Nagarwala, and Brian G. M. Durie. “Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics..” Clin Lymphoma Myeloma Leuk 15, no. 6 (June 2015): 368–76. https://doi.org/10.1016/j.clml.2014.12.002.
    Full Text Link to Item
  - Tuchman, Sascha A., Wendi A. Bacon, Li-Wen Huang, Gwynn Long, David Rizzieri, Mitchell Horwitz, John P. Chute, et al. “Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma..” J Clin Apher 30, no. 3 (June 2015): 176–82. https://doi.org/10.1002/jca.21360.
    Full Text Link to Item
  - Tuchman, Sascha A., Amy Lane, Whitney E. Hornsby, Caroline Bishop, Samantha Thomas, James E. Herndon, Gwynn Long, Cristina Gasparetto, and Lee W. Jones. “Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study..” Clin Lymphoma Myeloma Leuk 15, no. 2 (February 2015): 103–9. https://doi.org/10.1016/j.clml.2014.09.002.
    Full Text Link to Item
  - Sharma, Manish, Mei-Jie Zhang, Xiaobo Zhong, Muneer H. Abidi, Görgün Akpek, Ulrike Bacher, Natalie S. Callander, et al. “Older patients with myeloma derive similar benefit from autologous transplantation..” Biol Blood Marrow Transplant 20, no. 11 (November 2014): 1796–1803. https://doi.org/10.1016/j.bbmt.2014.07.013.
    Full Text Link to Item
  - Horwitz, Mitchell E., Nelson J. Chao, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, Cristina Gasparetto, John P. Chute, et al. “Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment..” J Clin Invest 124, no. 7 (July 2014): 3121–28. https://doi.org/10.1172/JCI74556.
    Full Text Link to Item
  - Saad, Ayman, Anuj Mahindra, Mei-Jie Zhang, Xiaobo Zhong, Luciano J. Costa, Angela Dispenzieri, William R. Drobyski, et al. “Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma..” Biol Blood Marrow Transplant 20, no. 3 (March 2014): 402-408.e1. https://doi.org/10.1016/j.bbmt.2013.12.557.
    Full Text Link to Item
  - Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, et al. “Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies..” Biol Blood Marrow Transplant 20, no. 2 (February 2014): 257–63. https://doi.org/10.1016/j.bbmt.2013.11.010.
    Full Text Link to Item
  - Saad, A., A. Mahindra, M. -. J. Zhang, X. Zhong, L. J. Costa, A. Dispenzieri, W. R. Drobyski, et al. “Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.” Biology of Blood and Marrow Transplantation 20, no. 3 (2014): 402–8.
  - Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, L. Lan, T. Shen, et al. “Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment..” Bone Marrow Transplant 48, no. 7 (July 2013): 926–31. https://doi.org/10.1038/bmt.2012.279.
    Full Text Link to Item
  - Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, et al. “Multiple myeloma, version 1.2013..” J Natl Compr Canc Netw 11, no. 1 (January 1, 2013): 11–17. https://doi.org/10.6004/jnccn.2013.0004.
    Full Text Link to Item
  - Kanda, Junya, Lun-Wei Chiou, Paul Szabolcs, Gregory D. Sempowski, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, et al. “Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation..” Biol Blood Marrow Transplant 18, no. 11 (November 2012): 1664-1676.e1. https://doi.org/10.1016/j.bbmt.2012.06.005.
    Full Text Link to Item
  - Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry..” Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, et al. “Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013..” J Natl Compr Canc Netw 10, no. 10 (October 1, 2012): 1211–19. https://doi.org/10.6004/jnccn.2012.0128.
    Full Text Link to Item
  - Horwitz, M. E., J. P. Chute, C. Gasparetto, G. D. Long, C. McDonald, A. Morris, D. A. Rizzieri, K. M. Sullivan, and N. J. Chao. “Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration..” Bone Marrow Transplant 47, no. 8 (August 2012): 1051–55. https://doi.org/10.1038/bmt.2011.217.
    Full Text Link to Item
  - Chen, D. -. F., V. K. Prasad, G. Broadwater, N. L. Reinsmoen, A. DeOliveira, A. Clark, K. M. Sullivan, et al. “Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors..” Bone Marrow Transplant 47, no. 6 (June 2012): 817–23. https://doi.org/10.1038/bmt.2011.181.
    Full Text Link to Item
  - Kanda, J., M. E. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. P. Chute, A. Morris, et al. “Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation..” Bone Marrow Transplant 47, no. 5 (May 2012): 700–705. https://doi.org/10.1038/bmt.2011.158.
    Full Text Link to Item
  - Tuchman, S. A., N. J. Chao, and C. G. Gasparetto. “Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma..” Adv Hematol 2012 (2012). https://doi.org/10.1155/2012/712613.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, et al. “Multiple myeloma..” J Natl Compr Canc Netw 9, no. 10 (October 2011): 1146–83. https://doi.org/10.6004/jnccn.2011.0095.
    Full Text Link to Item
  - Kanda, Junya, David A. Rizzieri, Cristina Gasparetto, Gwynn D. Long, John P. Chute, Keith M. Sullivan, Ashley Morris, et al. “Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning..” Biol Blood Marrow Transplant 17, no. 6 (June 2011): 867–74. https://doi.org/10.1016/j.bbmt.2010.09.009.
    Full Text Link to Item
  - Lokhorst, H., H. Einsele, D. Vesole, B. Bruno, J. San Miguel, J. A. Perez-Simon, N. M. Kröger, et al. “Reply to A. Gratwohl.” Journal of Clinical Oncology 29, no. 16 (June 1, 2011). https://doi.org/10.1200/JCO.2011.34.6718.
    Full Text
  - Craciunescu, Oana I., Beverly A. Steffey, Chris R. Kelsey, Nicole A. Larrier, Cathy J. Paarz-Largay, Robert G. Prosnitz, Nelson Chao, et al. “Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial..” Int J Radiat Oncol Biol Phys 79, no. 4 (March 15, 2011): 1248–55. https://doi.org/10.1016/j.ijrobp.2010.05.036.
    Full Text Link to Item
  - Rizzieri, David A., Christopher Crout, Robert Storms, Jared Golob, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, et al. “Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors..” Cancer Invest 29, no. 1 (January 2011): 56–61. https://doi.org/10.3109/07357907.2010.535055.
    Full Text Link to Item
  - Lokhorst, Henk, Hermann Einsele, David Vesole, Benedetto Bruno, Jesus San Miguel, Jose A. Pérez-Simon, Nicolaus Kröger, et al. “International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma..” J Clin Oncol 28, no. 29 (October 10, 2010): 4521–30. https://doi.org/10.1200/JCO.2010.29.7929.
    Full Text Link to Item
  - Rizzieri, David A., Robert Storms, Dong-Feng Chen, Gwynn Long, Yiping Yang, Daniel A. Nikcevich, Cristina Gasparetto, et al. “Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation..” Biol Blood Marrow Transplant 16, no. 8 (August 2010): 1107–14. https://doi.org/10.1016/j.bbmt.2010.02.018.
    Full Text Link to Item
  - Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy..” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
    Full Text Link to Item
  - Kumar, S. K., I. Flinn, S. J. Noga, P. Hari, R. Rifkin, N. Callander, M. Bhandari, et al. “Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study..” Leukemia 24, no. 7 (July 2010): 1350–56. https://doi.org/10.1038/leu.2010.116.
    Full Text Link to Item
  - Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma..” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, et al. “NCCN clinical practice guidelines in oncology: multiple myeloma..” J Natl Compr Canc Netw 7, no. 9 (October 2009): 908–42. https://doi.org/10.6004/jnccn.2009.0061.
    Full Text Link to Item
  - Anguiano, Ariel, Sascha A. Tuchman, Chaitanya Acharya, Kelly Salter, Cristina Gasparetto, Fenghuang Zhan, Madhav Dhodapkar, et al. “Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma..” J Clin Oncol 27, no. 25 (September 1, 2009): 4197–4203. https://doi.org/10.1200/JCO.2008.19.1916.
    Full Text Link to Item
  - Rizzieri, D. A., P. Dev, G. D. Long, C. Gasparetto, K. M. Sullivan, Ml Horwitz, J. Chute, and N. J. Chao. “Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors..” Bone Marrow Transplant 43, no. 4 (February 2009): 327–33. https://doi.org/10.1038/bmt.2008.321.
    Full Text Link to Item
  - Horwitz, Mitchell E., Ashley Morris, Cristina Gasparetto, Keith Sullivan, Gwynn Long, John Chute, David Rizzieri, Jackie McPherson, and Nelson Chao. “Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients..” Biol Blood Marrow Transplant 14, no. 5 (May 2008): 591–94. https://doi.org/10.1016/j.bbmt.2008.02.016.
    Full Text Link to Item
  - Byrne, B. J., M. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. Chute, N. J. Chao, and D. A. Rizzieri. “Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection..” Bone Marrow Transplant 41, no. 1 (January 2008): 39–43. https://doi.org/10.1038/sj.bmt.1705882.
    Full Text Link to Item
  - Horwitz, Mitchell E., Ivan Spasojevic, Ashley Morris, Marilyn Telen, James Essell, Cristina Gasparetto, Keith Sullivan, et al. “Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics..” Biol Blood Marrow Transplant 13, no. 12 (December 2007): 1422–26. https://doi.org/10.1016/j.bbmt.2007.08.050.
    Full Text Link to Item
  - Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution..” J Clin Oncol 25, no. 6 (February 20, 2007): 690–97. https://doi.org/10.1200/JCO.2006.07.0953.
    Full Text Link to Item
  - Lagoo, Anand S., Jerald Z. Gong, Timothy T. Stenzel, Barbara K. Goodman, Patrick J. Buckley, Nelson J. Chao, Cristina Gasparetto, Gwynn D. Long, and David A. Rizzieri. “Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment..” Arch Pathol Lab Med 130, no. 10 (October 2006): 1479–88. https://doi.org/10.1043/1543-2165(2006)130[1479:MEOSBM]2.0.CO;2.
    Full Text Link to Item
  - Nieto, Yago, James J. Vredenburgh, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, Nelson Chao, David Rizzieri, et al. “Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer..” Clin Cancer Res 10, no. 21 (November 1, 2004): 7136–43. https://doi.org/10.1158/1078-0432.CCR-04-0891.
    Full Text Link to Item
  - Chao, Nelson J., Liang-Piu Koh, Gwynn D. Long, Cristina Gasparetto, Mitchell Horwitz, Ashley Morris, Martha Lassiter, Keith M. Sullivan, and David A. Rizzieri. “Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens..” Biol Blood Marrow Transplant 10, no. 8 (August 2004): 569–75. https://doi.org/10.1016/j.bbmt.2004.05.001.
    Full Text Link to Item
  - Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma..” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
    Full Text Link to Item
  - Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma..” Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
    Full Text Link to Item
  - Snyder, Matthew J., Timothy T. Stenzel, Patrick J. Buckley, Anand S. Lagoo, David A. Rizzieri, Cristina Gasparetto, James J. Vredenburgh, Nelson J. Chao, and Jerald Z. Gong. “Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation..” Am J Surg Pathol 28, no. 6 (June 2004): 794–800. https://doi.org/10.1097/01.pas.0000126052.88174.f.
    Full Text Link to Item
  - Gasparetto, Cristina. “Stem cell transplantation for multiple myeloma..” Cancer Control 11, no. 2 (March 2004): 119–29. https://doi.org/10.1177/107327480401100218.
    Full Text Link to Item
  - Long, Gwynn D., Mary Laughlin, Bella Madan, Joanne Kurtzberg, Cristina Gasparetto, Ashley Morris, David Rizzieri, et al. “Unrelated umbilical cord blood transplantation in adult patients..” Biol Blood Marrow Transplant 9, no. 12 (December 2003): 772–80. https://doi.org/10.1016/j.bbmt.2003.08.007.
    Full Text Link to Item
  - Rizzieri, David A., Jeffrey T. Talbot, Gwynn D. Long, James J. Vredenburgh, Christina Gasparetto, Clayton S. Smith, Michael O. Colvin, et al. “4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia..” Biol Blood Marrow Transplant 9, no. 3 (March 2003): 183–88. https://doi.org/10.1053/bbmt.2003.50011.
    Full Text Link to Item
  - Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia..” Clin Cancer Res 9, no. 2 (February 2003): 663–68.
    Link to Item
  - McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia..” Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
    Full Text Link to Item
  - Gasparetto, Cristina, Maura Gasparetto, Michael Morse, Barbara Rooney, James J. Vredenburgh, Gwynn D. Long, David A. Rizzieri, Jennifer Loftis, Nelson J. Chao, and Clay Smith. “Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF..” Cytokine 18, no. 1 (April 7, 2002): 8–19. https://doi.org/10.1006/cyto.2002.1009.
    Full Text Link to Item
  - Chao, Nelson J., Cong X. Liu, Barbara Rooney, Benny J. Chen, Gwynn D. Long, James J. Vredenburgh, Ashley Morris, Cristina Gasparetto, and David A. Rizzieri. “Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells..” Biol Blood Marrow Transplant 8, no. 5 (2002): 249–56. https://doi.org/10.1053/bbmt.2002.v8.pm12064361.
    Full Text Link to Item
  - Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, T. T. Stenzel, P. Davis, and N. J. Chao. “Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen..” Blood 98, no. 12 (December 1, 2001): 3486–88. https://doi.org/10.1182/blood.v98.12.3486.
    Full Text Link to Item
  - Gasparetto, C., C. Smith, A. Gillio, A. M. Stoppa, M. A. Moore, and R. J. O’Reilly. “Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta..” Bone Marrow Transplant 14, no. 5 (November 1994): 717–23.
    Link to Item
  - Dennig, D., J. Lacerda, Y. Yan, C. Gasparetto, and R. J. O’Reilly. “ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7..” Cell Immunol 156, no. 2 (July 1994): 414–23. https://doi.org/10.1006/cimm.1994.1186.
    Full Text Link to Item
  - Gasparetto, C., C. Smith, M. Firpo, D. Dennig, T. Small, A. P. Gillio, R. Lichtenberg, R. J. O’Reilly, and M. A. Moore. “Dyshematopoiesis in combined immune deficiency with congenital neutropenia..” Am J Hematol 45, no. 1 (January 1994): 63–72. https://doi.org/10.1002/ajh.2830450110.
    Full Text Link to Item
  - Muench, M. O., C. Gasparetto, and M. A. Moore. “The in vitro growth of murine high proliferative potential-colony forming cells is not enhanced by growth in a low oxygen atmosphere..” Cytokine 4, no. 6 (November 1992): 488–94. https://doi.org/10.1016/1043-4666(92)90009-g.
    Full Text Link to Item
  - Crown, J., A. Jakubowski, N. Kemeny, M. Gordon, C. Gasparetto, G. Wong, C. Sheridan, G. Toner, B. Meisenberg, and J. Botet. “A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer..” Blood 78, no. 6 (September 15, 1991): 1420–27.
    Link to Item
  - Smith, C., C. Gasparetto, N. Collins, A. Gillio, M. O. Muench, R. J. O’Reilly, and M. A. Moore. “Purification and partial characterization of a human hematopoietic precursor population..” Blood 77, no. 10 (May 15, 1991): 2122–28.
    Link to Item
  - Lemoli, R. M., C. Gasparetto, D. A. Scheinberg, M. A. Moore, B. D. Clarkson, and S. C. Gulati. “Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination..” Blood 77, no. 8 (April 15, 1991): 1829–36.
    Link to Item
  - Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick, and R. J. O’Reilly. “Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates..” J Clin Invest 85, no. 5 (May 1990): 1560–65. https://doi.org/10.1172/JCI114605.
    Full Text Link to Item
  - Laver, J., E. Duncan, M. Abboud, C. Gasparetto, I. Sahdev, D. Warren, J. Bussel, P. Auld, R. J. O’Reilly, and M. A. Moore. “High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates..” J Pediatr 116, no. 4 (April 1990): 627–32. https://doi.org/10.1016/s0022-3476(05)81617-8.
    Full Text Link to Item
  - O’Reilly, R. J., A. Gillio, and C. Gasparetto. “Effects of hematopoietic growth factors following myeloablation in a primate model..” Int J Cell Cloning 8 Suppl 1 (January 1990): 262–67. https://doi.org/10.1002/stem.5530080724.
    Full Text Link to Item
  - Gasparetto, C., J. Laver, M. Abboud, A. Gillio, C. Smith, R. J. O’Reilly, and M. A. Moore. “Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model..” Blood 74, no. 2 (August 1, 1989): 547–50.
    Link to Item
  - Laver, J., M. Abboud, C. Gasparetto, A. Gillio, C. Smith, R. J. O’Reilly, and M. A. Moore. “Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy..” Biotherapy 1, no. 4 (1989): 293–300. https://doi.org/10.1007/bf02171005.
    Full Text Link to Item
- Conference Papers
  - Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Gwynn D. Long, Richard Lopez, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning..” In Biol Blood Marrow Transplant, 23:1949–54, 2017. https://doi.org/10.1016/j.bbmt.2017.06.027.
    Full Text Link to Item
  - Richardson, Paul G., Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, et al. “PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma..” In Blood, 122:2331–37, 2013. https://doi.org/10.1182/blood-2013-01-481325.
    Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Industry Relationships

Selected Publications

Academic Articles

Conference Papers